Clinical Trials List
2025-02-28 - 2032-06-30
Phase III
Recruiting13
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 甘蓉瑜 無
- 高理鈞 無
- Shen Liang Shih 無
- Junping Shiau Shiau 無
- Chung-Liang Li 無
- Fang-Ming Chen 無
- 巫承哲 無
- Chieh-Han Chuang 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張端瑩 無
- Wei-Wu Chen 無
- YEN-SHEN LU 無
- 林柏翰 無
- 陳怡君 無
- 蔡立威 無
- 林季宏 無
- SUNG-HSIN KUO 無
- 楊明翰 無
- MING-YANG WANG 無
- 郭文宏 無
- 黃柏翔 無
- 羅喬 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 馮晉榮
- Yi-Fang Tsai 無
- 林燕淑
- Chun-Yu Liu 無
- Jiun-I Lai 無
- 陳柏方
- Ta-Chung Chao
- 賴亦貞 無
- 陳彥蓁
- Chi-Cheng Huang
- 鄭涵方 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chen-Teng Wu 無
- 黃至豪 無
- Chih-Jung Chen 無
- Yao-Chung Wu 無
- 蘇孟夏 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
47 participants
-
Global
4220 participants
